The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib

American Journal of Therapeutics

Volumn 7, Issue 3, 2000, Pages 153-158

  Maddrey, W C ^a,c   Maurath, C J ^b   Verburg, K M ^b   Geis, G S ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Celecoxib; COX 2 inhibitors; Hepatic toxicity; Nonsteroidal anti inflammatory drugs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; LIVER; METABOLISM; OSTEOARTHRITIS; PAIN; PATHOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CONTROLLED CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LIVER; MEMBRANE PROTEINS; OSTEOARTHRITIS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0034189399     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007030-00003     Document Type: Article

References (23)

1. Brass EP: Hepatic toxicity of antirheumatic drugs. Cleve Clin J Med 1993;60:466-472.
2. Walker AM: Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammmatory drugs. Arthritis Rheum 1997;40:201-208.
3. Tolman KG: Hepatotoxicity of non-narcotic analgesics. Am J Med 1998;105:13S-19S.
4. Whelton A, Stout RL, Spilman PS, et al.: Renal effects of ibuprofen, piroxicam and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med 1990;112:568-598.
5. Scully LJ, Clarke D, Barr RJ: Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;38:744-751.
6. Hackstein H, Mohl W, Püschel W, et al: Diclofenac-associated acute cholestatic hepatitis. Z Gastroenterol 1998;36:385-389.
7. Iveson TJ, Ryley NG, Kelly PM, et al: Diclofenac associated hepatitis. J Hepatol 1990;10:85-89.
8. Zaragoza Marcet A, Alfonso Moreno V, Roig Catalá E: NSAID-induced hepatotoxicity: aceclofenac and diclofenac. Rev Esp Enferm Dig 1995;87:472-475.
9. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J: Diclofenac-associated hepatotoxicity. JAMA 1990;264: 2660-2662.
10. Breen EG, McNicholl J, Cosgrove E, et al: Fatal hepatitis associated with diclofenac. Gut 1986;11:1390-1393.
11. Schapira D, Bassan L, Nahir AM, Scharf Y: Diclofenac-induced hepatotoxicity. Postgrad Med J 1986;62:63-65.
12. Banks AT, Zimmerman HJ, Ishak KG, Harter JG: Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995;22:820-827.
13. Victorino RM, Silveira JC, Baptista A, de Moura MC: Jaundice associated with naproxen. Postgrad Med J 1980;56:368-370.
14. Riley TR, Smith JP: Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998;93:1563-1565.
15. Miwa LJ, Jones JK, Pathiyal A, et al.: Value of epidemiologic studies in determining the true incidence of adverse events. The non-steroidal anti-inflammatory drug story. Arch Intern Med 1997;157:2129-2136.
16. Simon LS, Lanza FL, Lipsky PE, et al.: Preliminary study of the safety and efficacy of celecoxib, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-1602.
17. Geis GS, Stead H, Morant SV, et al: Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998;41(Suppl 9): S316: Abstract 1699.
18. Geis GS, Hubbard RC, Callison DA, et al: Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41(Suppl 9):S364:Abstract 1990.
19. Pugh RNH, Murray-Lyon IM, Dawson JL, et al.: Transection of the oesophagus for bleeding varices. Br J Surg 1973;60:646-649.
20. Singh G, Fries JF, Williams CA, et al: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-194.
21. Tolman KG: Hepatotoxicity of antirheumatic drugs. J Rheumatol 1990;22:6-11.
22. Kevat S, Ahern M, Hall P: Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicpl Adverse Drug Exp 1988;3:197-208.
23. Shergy WJ, Polisson RP, Caldwell DS, et al: Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85:771-774.